Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Marinus ( (MRNS) ) has provided an announcement.
Marinus Pharmaceuticals has entered into a merger agreement with Immedica Pharma AB, where Immedica’s subsidiary will acquire all outstanding shares of Marinus at $0.55 per share. The merger, expected to close in the first quarter of 2025, will result in Marinus becoming a wholly-owned subsidiary of Immedica, impacting its market position and stakeholder interests.
More about Marinus
Marinus Pharmaceuticals, Inc. is a Delaware-based company operating in the pharmaceuticals industry.
YTD Price Performance: -96.59%
Average Trading Volume: 2,769,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.5M
Learn more about MRNS stock on TipRanks’ Stock Analysis page.
